Project details

The COBALT trial aims to find out if adding Memantine to acetylcholinesterase inhibitors improves overall health and functioning for people with DLB or PDD.

 

About the study:

COmBining memantine And cholinesterase inhibitors in Lewy body dementia Treatment trial (COBALT) is a clinical trial, which aims to find out if adding Memantine to a cholinesterase inhibitor (either donepezil, rivastigmine and galantamine) improves overall health and functioning for people with Dementia with Lewy Bodies (DLB) or Parkinson’s Disease Dementia. (PDD)

 

Who can take part?

• Individuals who have a probable diagnosis of DLB or PDD
• Aged 55years +
• Taking a cholinesterase inhibitor (either donepezil, rivastigmine and galantamine) for at least 12 weeks
• If receiving any antiparkinsonian treatment, antidepressants, anxiolytics, antipsychotics, or other drugs with significant psychotropic effects then dose must be stable for a minimum of 4 weeks prior to enrolment with no significant changes expected during the enrolment period
• Have a caregiver/ informant

There are further inclusion and exclusion criteria, if you are interested in hearing more, we can discuss these with you.

 

What does this study involve?

 If you agree to take part you will join one of two trial treatment groups for 12 months:

- a placebo (‘dummy’ drug) group

OR

- a medication (Memantine) group

You will have planned visits and phone calls with the local trial team, who will ask you about your symptoms, how you feel and your study treatment.

A family member or person who knows you well will also be asked to answer questions about your symptoms and about how they are feeling.

 

How can I take part?

Contact  researchinfo@nsft.nhs.uk

 

Click here to find out more about research opportunities